Nevro

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

You can watch Nevro and buy or sell other stocks, ETFs, and their options commission-free!

About NVRO

Nevro Corp. engages in the development of medical devices. The firm focuses on providing products that improve the quality of life of patients suffering from debilitating chronic pain. 

CEO
Kevin R. Thornal
CEOKevin R. Thornal
Employees
Employees
Headquarters
Redwood City, California
HeadquartersRedwood City, California
Founded
2006
Founded2006
Employees
Employees

NVRO Key Statistics

Market cap
224.09M
Market cap224.09M
Price-Earnings ratio
-1.91
Price-Earnings ratio-1.91
Dividend yield
Dividend yield
Average volume
1.06M
Average volume1.06M
High today
High today
Low today
Low today
Open price
Open price
Volume
0.00
Volume0.00
52 Week high
$13.84
52 Week high$13.84
52 Week low
$3.17
52 Week low$3.17

Stock Snapshot

With a market cap of 224.09M, Nevro(NVRO) trades at $5.84. The stock has a price-to-earnings ratio of -1.91.

During the trading day, Nevro(NVRO) stock saw an opening price of —, a peak of —, and a bottom of —.

Trading volume for Nevro(NVRO) stock has reached 0, versus its average volume of 1.06M.

The stock's 52-week range extends from a low of $3.17 to a high of $13.84.

The stock's 52-week range extends from a low of $3.17 to a high of $13.84.

People also own

Based on the portfolios of people who own NVRO. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.